V3-specific neutralizing antibodies in sera from HIV-1 gp160-immunized volunteers block virus fusion and act synergistically with human monoclonal antibody to the conformation-dependent CD4 binding site of gp120. NIH-NIAID AIDS Vaccine Clinical Trials Network.
Authors
Discussion
Loading...
Member takes
Implication
Key Points
Key points are not available for this paper at this time.
Cite This Study
Montefiori et al. (1993) studied this question.